1 Ocak 2020 Dergi makalesi Açık Erişim

Ersan, Ronak Haj; Alagoz, Mehmet Abdullah; Dogen, Aylin; Duran, Nizami; Burmaoglu, Serdar; Algul, Oztekin

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/6523</identifier>
  <creators>
    <creator>
      <creatorName>Ersan, Ronak Haj</creatorName>
      <givenName>Ronak Haj</givenName>
      <familyName>Ersan</familyName>
      <affiliation>Mersin Univ, Dept Pharmaceut Chem, Fac Pharm, TR-33169 Mersin, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Alagoz, Mehmet Abdullah</creatorName>
      <givenName>Mehmet Abdullah</givenName>
      <familyName>Alagoz</familyName>
      <affiliation>Inonu Univ, Dept Pharmaceut Chem, Fac Pharm, Malatya, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Dogen, Aylin</creatorName>
      <givenName>Aylin</givenName>
      <familyName>Dogen</familyName>
      <affiliation>Mersin Univ, Dept Pharmaceut Microbiol, Fac Pharm, Mersin, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Duran, Nizami</creatorName>
      <givenName>Nizami</givenName>
      <familyName>Duran</familyName>
      <affiliation>Mustafa Kemal Univ, Fac Med, Dept Med Microbiol, Antakya, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Burmaoglu, Serdar</creatorName>
      <givenName>Serdar</givenName>
      <familyName>Burmaoglu</familyName>
      <affiliation>Ataturk Univ, Dept Chem, Fac Sci, TR-25240 Erzurum, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Algul, Oztekin</creatorName>
      <givenName>Oztekin</givenName>
      <familyName>Algul</familyName>
      <affiliation>Mersin Univ, Dept Pharmaceut Chem, Fac Pharm, TR-33169 Mersin, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Bisbenzoxazole Derivatives: Design, Synthesis, In Vitro Antimicrobial, Antiproliferative Activity, And Molecular Docking Studies</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2020</publicationYear>
  <dates>
    <date dateType="Issued">2020-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/6523</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1080/10406638.2020.1852589</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Four series of bisbenzoxazole derivatives were designed, synthesized, and screened for antiproliferative and antimicrobial activities. Generally, all synthesized bisbenzoxazoles (9-24) displayed significant antiproliferative activity; these effects were shown to be related to oxazole rings and substituents in bisbenzoxazole compounds. Especially, the series bearing chloro-substituent (9-12) exhibited better antiproliferative activity with higher selectivity than the other series (13-24); the IC50 values were observed in the range of 0.045-0.342 mu M. Interestingly, only the compound with a nitro substituent (22) showed maximum potency with an IC50 value of 0.011 mu M, which is two-fold more active than the standard drug methotrexate, with moderate selectivity. The compounds bearing fluoro-substituent (14-16) were found to exhibit potent antibacterial activity against the Gram-positive Enterococcus faecalis, with a MIC value of 62.5 mu g/mL, and moderate activity against Gram-negative bacteria and fungi. Only the compound 23 showed potent activity against Escherichia coli, with a MIC value of 62.5 mu g/mL. In order to better evaluate the activity results, crystal structures of five different proteins Human Anaplastic Lymphoma Kinase (PDB ID: 2XP2), CYP2C8dH complexed (PDB ID: 2NNI), factor-human kinase-beta enzyme IKK-beta enzyme (PDB ID: 4KIK), a tubulin heterodimer complex containing alpha and beta sub-units (PDB ID: 1Z2B) and penicillin-binding protein 4 (PBP4) from Enterococcus faecalis (PDB ID: 6MKI) were used in the docking study to examine antiproliferative and antimicrobial activity. Finally, an ADMET screening test was applied to determine the drug-like, toxicological, and optimum physicochemical properties for all of the synthesized compounds. The strategy applied in this research may act as a perspective for the rational design of potential anticancer drugs.</description>
  </descriptions>
</resource>